title: Antibodies against cyclic citrullinated peptide don't decrease after 6 months of infliximab treatment in refractory rheumatoid arthritis.
abstract: Anti-citrullinated peptide antibodies (ACPA) and the rheumatoid factor (RF) are well-established serological markers for rheumatoid arthritis (RA). ACPA are very useful in the diagnosis of RA, especially at the early stages of the disease when ACPA have a greater diagnostic value than RF. The aim of the study was to assess the influence of infliximab treatment on RF IgM and ACPA serum levels and RA activity during 6 months of treatment. Thirty-two patients with refractory RA were treated with infliximab during a 6-month period. At baseline, 3 and 6 months of treatment the patients were examined for the number swollen and tender joints out of 28 (SJC, TJC) and the visual analogue scale of arthritis activity according to the patient (VAS). Serum samples were tested for erythrocyte sedimentation rate (ESR), C-reactive protein level (CRP), ACPA and RF IgM. The disease activity score (DAS-28) parameter was also calculated at the same time. During the course of our study, we observed statistically significant improvement in ESR, CRP, TJC, SJC, VAS DAS-28, and RF IgM after 3 and 6 months of infliximab treatment when compared to the baseline, whereas the ACPA level remained unchanged after 3 and 6 months of treatment (P = 0.96 and P = 0.85). The changes in the ACPA level are not a factor for evaluation of successful infliximab treatment but the changes in RF IgM are. According to different behavior of these antibodies during infliximab treatment, we suggest that the roles of ACPA and RF in the pathogenesis of RA are different.
authors.affiliation: Department of Family Medicine, Medical University of Lublin, ul. Staszica 11, 20-081 Lublin, Poland. kolbo@wp.pl
authors.forename: Bogdan
authors.initials: B
authors.lastname: Kolarz
authors.forename: Maria
authors.initials: M
authors.lastname: Majdan
authors.forename: Magdalena
authors.initials: M
authors.lastname: Dryglewska
authors.forename: Dorota
authors.initials: D
authors.lastname: Darmochwal-Kolarz
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology*; D001323:Autoantibodies / Q000097:blood* / Q000276:immunology; D002738:Chloroquine / Q000627:therapeutic use; D004351:Drug Resistance / Q000276:immunology; D004359:Drug Therapy, Combination; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007075:Immunoglobulin M / Q000097:blood / Q000276:immunology; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000069285:Infliximab; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D010456:Peptides, Cyclic / Q000276:immunology*; D012217:Rheumatoid Factor / Q000097:blood / Q000276:immunology; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D001323:Autoantibodies; D005938:Glucocorticoids; D007075:Immunoglobulin M; D007166:Immunosuppressive Agents; D010456:Peptides, Cyclic; C487763:cyclic citrullinated peptide; D002738:Chloroquine; D012217:Rheumatoid Factor; D000069285:Infliximab; D008727:Methotrexate
references.citation: Ann Rheum Dis. 2008 Sep;67(9):1347-50
references.pmid: 18388157
references.citation: Arthritis Res Ther. 2006;8(1):R3
references.pmid: 16356192
references.citation: Arthritis Rheum. 2004 Jul;50(7):2113-21
references.pmid: 15248208
references.citation: Arthritis Res Ther. 2006;8(1):R19
references.pmid: 16507117
references.citation: Arthritis Rheum. 2003 Oct;48(10):2741-9
references.pmid: 14558078
references.citation: Arthritis Rheum. 2004 Dec;50(12):3776-82
references.pmid: 15593224
references.citation: J Immunol. 1999 Aug 1;163(3):1521-8
references.pmid: 10415055
references.citation: Ann Rheum Dis. 2005 Feb;64(2):299-302
references.pmid: 15166003
references.citation: Ann Rheum Dis. 2004 Oct;63(10):1218-21
references.pmid: 15361374
references.citation: Scand J Rheumatol. 2003;32(4):197-204
references.pmid: 14626625
references.citation: Arthritis Rheum. 2000 Aug;43(8):1831-5
references.pmid: 10943873
references.citation: Ann Rheum Dis. 2005 Aug;64(8):1224-6
references.pmid: 16014683
references.citation: Arthritis Res Ther. 2007;9(5):R103
references.pmid: 17922913
references.citation: Ann Rheum Dis. 2009 Jan;68(1):69-74
references.pmid: 18375541
references.citation: Arthritis Rheum. 2000 Jan;43(1):155-63
references.pmid: 10643712
references.citation: Ann Rheum Dis. 2003 Sep;62(9):870-4
references.pmid: 12922961
references.citation: Joint Bone Spine. 2009 May;76(3):248-53
references.pmid: 19208451
references.citation: Rheumatol Int. 2005 Nov;26(1):58-62
references.pmid: 15726373
references.citation: Biochem Biophys Res Commun. 1998 Feb 24;243(3):641-6
references.pmid: 9500980
references.citation: J Rheumatol. 2008 Mar;35(3):425-8
references.pmid: 18322974
references.citation: Ann Rheum Dis. 2004 Dec;63(12):1587-93
references.pmid: 15547083
references.citation: Arthritis Rheum. 2007 Oct;56(10):3226-35
references.pmid: 17907167
references.citation: Arthritis Rheum. 2004 Feb;50(2):380-6
references.pmid: 14872479
references.citation: Arthritis Rheum. 2005 Nov;52(11):3424-32
references.pmid: 16255019
references.citation: Ann Rheum Dis. 2002 Aug;61(8):723-5
references.pmid: 12117680
references.citation: Lancet. 1999 Dec 4;354(9194):1932-9
references.pmid: 10622295
references.citation: J Rheumatol. 2006 Mar;33(3):497-500
references.pmid: 16511906
references.citation: Science. 2004 Oct 8;306(5694):279-83
references.pmid: 15345777
references.citation: J Rheumatol. 1998 Mar;25(3):417-26
references.pmid: 9517757
references.citation: Annu Rev Med. 2000;51:207-29
references.pmid: 10774461
references.citation: Ann Rheum Dis. 2005 Dec;64(12):1744-9
references.pmid: 15843452
references.citation: Ann Rheum Dis. 2005 Jul;64(7):1003-8
references.pmid: 15958758